Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

VSMPO-AVISMA fell under US sanctions

9/25/23 VSMO

VinLab launched an online service for corporate clients

9/25/23 BELU

Sovcomflot expects the global tanker shortage to persist

9/25/23 FLOT

Gazprombank restructured Mechel's debt

9/25/23 MTLR

Kamaz presented its first career unmanned dump truck

9/25/23 KMAZ

Exchange of Noventiq receipts for Softline shares completed

9/25/23 SFTL

Exchange of Noventiq receipts for Softline shares completed

9/25/23 SOFL

Inter RAO expects electricity exports to decline by 19% year-on-year

9/25/23 IRAO

Andrey Molchanov again transferred 10% of LSR shares to his son Egor

9/25/23 LSRG

PIK bought a part of the territory of the wine and cognac enterprise

9/25/23 PIKK